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Note
 Yellow font/highlight in the presentation is used 
to indicate changes to the resolution in 
comparison to the prior approved version.
Purpose of the Resolution
 The purpose of this resolution is to update the 
table of inactivated influenza vaccines in the 
VFC program. 
A. Inactivated Influenza Vaccine
Eligible Groups
All children aged 6 months through 18 years.
Recommended Vaccination Schedule
– 6 months through 8 years:  1 or 2 doses, as noted in the current 
ACIP recommendations 
– 9 through 18 years:  1 dose 
A. Inactivated Influenza Vaccine
The table below lists the currently approved inactivated influenza 
vaccines in the VFC program, including  the age indications for each 
vaccine.    
[
Note:  The use of brand names is not meant to preclude the use of other 
comparable licensed vaccines.
Brand Name Presentation Age Indication
Afluria (Quadrivalent) 0.25mL pre-filled syringe 6 through 35 months
Afluria (Quadrivalent) 0.5 mL pre-filled syringe >= 36 months
Afluria (Quadrivalent) 5.0mL multi-dose vial >=6 months
Fluarix (Quadrivalent) 0.5 mL pre-filled syringe >= 6 months
Flucelvax (Quadrivalent) 0.5 mL pre-filled syringe >= 4 years
Flucelvax (Quadrivalent) 5.0mL multi-dose vial >= 4 years
Flulaval (Quadrivalent) 0.5 mL pre-filled syringe >= 6 months
Flulaval (Quadrivalent) 5.0 mL multi-dose vial >= 6 months
Fluzone (Quadrivalent) 0.25mL pre-filled syringe >= 6 through 35 months
Fluzone (Quadrivalent) 0.5mL prefilled syringe/single-dose vial >= 6 months
Fluzone (Quadrivalent) 5.0mL multi-dose vial >= 6 months
A. Inactivated Influenza Vaccine
Recommended Intervals/Recommended Dosage
Recommended Intervals
 Minimum Age: 6 months 
 Minimum interval between dose 1 and dose 2 (where 
applicable): 4 weeks
Recommended Dosage
 Refer to product package insert.
A. Inactivated Influenza Vaccine
Contraindications and Precautions
Contraindications:
 History of severe allergic reaction to any component of the vaccine 
or after previous dose of any influenza vaccine.  However, ACIP 
makes specific recommendations for the use of influenza vaccine in 
persons with egg allergy (see Influenza Vaccination of Persons with 
a History of Egg Allergy, in 
https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm).
Precautions:
 Moderate or severe acute illness with or without fever
 GBS within 6 weeks following a previous dose of influenza vaccine
B. Live Attenuated Influenza Vaccine
Eligible Groups
All healthy, non-pregnant children and adolescents (i.e., those who do 
not have an underlying medical condition that predisposes them to 
influenza complications) aged 2 through 18 years.
Recommended Vaccination Schedule
–
–
2 through 8 years:  1 or 2 doses, as noted in the current ACIP 
recommendations 
9 through 18 years:  1 dose 
B. Live Attenuated Influenza Vaccine
Recommended Intervals/Recommended Dosage
Recommended Intervals
 Minimum Age: 2 years
 Minimum interval between dose 1 and dose 2 (where 
applicable): 4 weeks
Recommended Dosage
 Refer to product package insert.
B. Live Attenuated Influenza  
Vaccine
Contraindications and Precautions
Contraindications and precautions can be found at:
https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm
Statement Regarding Update Based on 
Published  Documents
 [If an ACIP recommendation regarding influenza 
vaccination is published within 6 months 
following this resolution, the relevant language 
above (except in the eligible groups sections) 
will be replaced with the language in the 
recommendation and incorporated by reference 
to the URL.]
